Better response with add-on clarithromycin does not translate to survival gains in multiple myeloma
13 Dec 2019
byJairia Dela Cruz
In the treatment of stem cell transplant-ineligible patients with newly diagnosed multiple myeloma (MM), the addition of clarithromycin to lenalidomide and dexamethasone yields marked improvements in response rates that, however, do not equate to better survival, as shown in the results of the phase III GEM-Claridex trial.